# Fair Isaac Corp: financial statements, quarterly

FICO · NYSE · CIK 814547 · [Industrials](/sectors/industrials.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/fico.md) · [Financials](/companies/fico/financials.md) · [Filings](/companies/fico/filings.md) · [Insiders](/companies/fico/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/fico/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [390 d](/filings/0000814547-25-000030.md) | [382](/filings/0000814547-25-000008.md) | [434](/filings/0000814547-25-000014.md) | [448](/filings/0000814547-25-000022.md) | [454 d](/filings/0000814547-25-000030.md) | [440](/filings/0000814547-26-000011.md) | [499](/filings/0000814547-26-000021.md) | [536](/filings/0000814547-26-000030.md) | [516 d](/filings/0000814547-25-000030.md) | [512](/filings/0000814547-26-000011.md) | [692](/filings/0000814547-26-000021.md) | [674](/filings/0000814547-26-000030.md) |
| Cost of revenue | $m | [82.8 d](/filings/0000814547-25-000030.md) | [83.5](/filings/0000814547-25-000008.md) | [86.9](/filings/0000814547-25-000014.md) | [88.2](/filings/0000814547-25-000022.md) | [89.6 d](/filings/0000814547-25-000030.md) | [87.3](/filings/0000814547-26-000011.md) | [87.6](/filings/0000814547-26-000021.md) | [87.6](/filings/0000814547-26-000030.md) | [91.2 d](/filings/0000814547-25-000030.md) | [87.3](/filings/0000814547-26-000011.md) | [91.2](/filings/0000814547-26-000021.md) | [87.0](/filings/0000814547-26-000030.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [41.6 d](/filings/0000814547-25-000030.md) | [42.6](/filings/0000814547-25-000008.md) | [40.9](/filings/0000814547-25-000014.md) | [44.2](/filings/0000814547-25-000022.md) | [44.2 d](/filings/0000814547-25-000030.md) | [45.1](/filings/0000814547-26-000011.md) | [45.0](/filings/0000814547-26-000021.md) | [47.2](/filings/0000814547-26-000030.md) | [51.0 d](/filings/0000814547-25-000030.md) | [49.9](/filings/0000814547-26-000011.md) | [53.9](/filings/0000814547-26-000021.md) | [53.7](/filings/0000814547-26-000030.md) |
| Selling, general and administrative | $m | [99.3 d](/filings/0000814547-25-000030.md) | [104](/filings/0000814547-25-000008.md) | [111](/filings/0000814547-25-000014.md) | [125](/filings/0000814547-25-000022.md) | [123 d](/filings/0000814547-25-000030.md) | [128](/filings/0000814547-26-000011.md) | [120](/filings/0000814547-26-000021.md) | [139](/filings/0000814547-26-000030.md) | [126 d](/filings/0000814547-25-000030.md) | [141](/filings/0000814547-26-000011.md) | [144](/filings/0000814547-26-000021.md) | [171](/filings/0000814547-26-000030.md) |
| Operating income | $m | [166 d](/filings/0000814547-25-000030.md) | [151](/filings/0000814547-25-000008.md) | [195](/filings/0000814547-25-000014.md) | [190](/filings/0000814547-25-000022.md) | [197 d](/filings/0000814547-25-000030.md) | [180](/filings/0000814547-26-000011.md) | [246](/filings/0000814547-26-000021.md) | [263](/filings/0000814547-26-000030.md) | [237 d](/filings/0000814547-25-000030.md) | [234](/filings/0000814547-26-000011.md) | [402](/filings/0000814547-26-000021.md) | [363](/filings/0000814547-26-000030.md) |
| Interest expense | $m | [24.3 d](/filings/0001628280-24-045719.md) | [24.2](/filings/0000814547-25-000008.md) | [26.1](/filings/0000814547-25-000014.md) | [26.9](/filings/0000814547-24-000024.md) | [28.5 d](/filings/0001628280-24-045719.md) | [29.5](/filings/0000814547-25-000008.md) | [31.4](/filings/0000814547-25-000014.md) | [32.9](/filings/0000814547-26-000030.md) | [39.9 d](/filings/0000814547-25-000030.md) | [42.0](/filings/0000814547-26-000011.md) | [44.6](/filings/0000814547-26-000021.md) | [59.9](/filings/0000814547-26-000030.md) |
| Income tax | $m | [39.0 d](/filings/0000814547-25-000030.md) | [9.5](/filings/0000814547-25-000008.md) | [42.9](/filings/0000814547-25-000014.md) | [41.1](/filings/0000814547-25-000022.md) | [35.7 d](/filings/0000814547-25-000030.md) | [(2.4)](/filings/0000814547-26-000011.md) | [50.4](/filings/0000814547-26-000021.md) | [55.2](/filings/0000814547-26-000030.md) | [47.4 d](/filings/0000814547-25-000030.md) | [33.6](/filings/0000814547-26-000011.md) | [91.6](/filings/0000814547-26-000021.md) | [77.5](/filings/0000814547-26-000030.md) |
| Net income | $m | [101 d](/filings/0000814547-25-000030.md) | [121](/filings/0000814547-25-000008.md) | [130](/filings/0000814547-25-000014.md) | [126](/filings/0000814547-25-000022.md) | [136 d](/filings/0000814547-25-000030.md) | [153](/filings/0000814547-26-000011.md) | [163](/filings/0000814547-26-000021.md) | [182](/filings/0000814547-26-000030.md) | [155 d](/filings/0000814547-25-000030.md) | [158](/filings/0000814547-26-000011.md) | [264](/filings/0000814547-26-000021.md) | [237](/filings/0000814547-26-000030.md) |
| Diluted EPS | $ per share | not reported | [4.80](/filings/0000814547-25-000008.md) | [5.16](/filings/0000814547-25-000014.md) | [5.05](/filings/0000814547-25-000022.md) | not reported | [6.14](/filings/0000814547-26-000011.md) | [6.59](/filings/0000814547-26-000021.md) | [7.40](/filings/0000814547-26-000030.md) | not reported | [6.61](/filings/0000814547-26-000011.md) | [11.14](/filings/0000814547-26-000021.md) | [10.45](/filings/0000814547-26-000030.md) |
| Basic EPS | $ per share | not reported | [4.89](/filings/0000814547-25-000008.md) | [5.23](/filings/0000814547-25-000014.md) | [5.12](/filings/0000814547-25-000022.md) | not reported | [6.26](/filings/0000814547-26-000011.md) | [6.67](/filings/0000814547-26-000021.md) | [7.49](/filings/0000814547-26-000030.md) | not reported | [6.68](/filings/0000814547-26-000011.md) | [11.19](/filings/0000814547-26-000021.md) | [10.46](/filings/0000814547-26-000030.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [137](/filings/0001628280-24-045719.md) | [160](/filings/0000814547-24-000005.md) | [136](/filings/0000814547-24-000016.md) | [156](/filings/0000814547-24-000024.md) | [151](/filings/0000814547-25-000030.md) | [184](/filings/0000814547-25-000008.md) | [147](/filings/0000814547-25-000014.md) | [189](/filings/0000814547-25-000022.md) | [134](/filings/0000814547-26-000030.md) | [162](/filings/0000814547-26-000011.md) | [219](/filings/0000814547-26-000021.md) | [248](/filings/0000814547-26-000030.md) |
| Current assets | $m | [556](/filings/0001628280-24-045719.md) | [565](/filings/0000814547-24-000005.md) | [641](/filings/0000814547-24-000016.md) | [631](/filings/0000814547-24-000024.md) | [617](/filings/0000814547-25-000030.md) | [596](/filings/0000814547-25-000008.md) | [725](/filings/0000814547-25-000014.md) | [710](/filings/0000814547-25-000022.md) | [705](/filings/0000814547-26-000030.md) | [699](/filings/0000814547-26-000011.md) | [901](/filings/0000814547-26-000021.md) | [882](/filings/0000814547-26-000030.md) |
| Total assets | $m | [1,575](/filings/0001628280-24-045719.md) | [1,594](/filings/0000814547-24-000005.md) | [1,703](/filings/0000814547-24-000016.md) | [1,709](/filings/0000814547-24-000024.md) | [1,718](/filings/0000814547-25-000030.md) | [1,707](/filings/0000814547-25-000008.md) | [1,836](/filings/0000814547-25-000014.md) | [1,862](/filings/0000814547-25-000022.md) | [1,868](/filings/0000814547-26-000030.md) | [1,854](/filings/0000814547-26-000011.md) | [2,048](/filings/0000814547-26-000021.md) | [2,037](/filings/0000814547-26-000030.md) |
| Current liabilities | $m | [368](/filings/0001628280-24-045719.md) | [433](/filings/0000814547-24-000005.md) | [315](/filings/0000814547-24-000016.md) | [337](/filings/0000814547-24-000024.md) | [380](/filings/0000814547-25-000030.md) | [331](/filings/0000814547-25-000008.md) | [343](/filings/0000814547-25-000014.md) | [771](/filings/0000814547-25-000022.md) | [849](/filings/0000814547-26-000030.md) | [752](/filings/0000814547-26-000011.md) | [405](/filings/0000814547-26-000021.md) | [745](/filings/0000814547-26-000030.md) |
| Total liabilities | $m | [2,263](/filings/0001628280-24-045719.md) | [2,319](/filings/0000814547-24-000005.md) | [2,439](/filings/0000814547-24-000016.md) | [2,538](/filings/0000814547-24-000024.md) | [2,681](/filings/0000814547-25-000030.md) | [2,845](/filings/0000814547-25-000008.md) | [2,960](/filings/0000814547-25-000014.md) | [3,259](/filings/0000814547-25-000022.md) | [3,614](/filings/0000814547-26-000030.md) | [3,662](/filings/0000814547-26-000011.md) | [4,150](/filings/0000814547-26-000021.md) | [6,135](/filings/0000814547-26-000030.md) |
| Long-term debt | $m | [1,812](/filings/0001628280-24-045719.md) | [1,809](/filings/0000814547-24-000005.md) | [2,029](/filings/0000814547-24-000016.md) | [2,105](/filings/0000814547-24-000024.md) | [2,194](/filings/0000814547-25-000030.md) | [2,406](/filings/0000814547-25-000008.md) | [2,513](/filings/0000814547-25-000014.md) | [2,380](/filings/0000814547-25-000022.md) | [2,656](/filings/0000814547-26-000030.md) | [2,797](/filings/0000814547-26-000011.md) | [3,639](/filings/0000814547-26-000021.md) | [5,282](/filings/0000814547-26-000030.md) |
| Current portion of debt | $m | [50.0](/filings/0001628280-24-045719.md) | [153](/filings/0000814547-24-000005.md) | [15.0](/filings/0000814547-24-000016.md) | [15.0](/filings/0000814547-24-000024.md) | [15.0](/filings/0000814547-25-000030.md) | [15.0](/filings/0000814547-25-000008.md) | [15.0](/filings/0000814547-25-000014.md) | [399](/filings/0000814547-25-000022.md) | [400](/filings/0000814547-26-000030.md) | [400](/filings/0000814547-26-000011.md) | [0.0](/filings/0000814547-26-000021.md) | [300](/filings/0000814547-26-000030.md) |
| Shareholders' equity | $m | [(688)](/filings/0000814547-25-000030.md) | [(726)](/filings/0000814547-25-000014.md) | [(736)](/filings/0000814547-25-000022.md) | [(829)](/filings/0000814547-25-000022.md) | [(963)](/filings/0000814547-26-000030.md) | [(1,138)](/filings/0000814547-26-000021.md) | [(1,124)](/filings/0000814547-26-000030.md) | [(1,397)](/filings/0000814547-26-000030.md) | [(1,746)](/filings/0000814547-26-000030.md) | [(1,808)](/filings/0000814547-26-000021.md) | [(2,102)](/filings/0000814547-26-000030.md) | [(4,097)](/filings/0000814547-26-000030.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:DebtCurrent, us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [164 d](/filings/0000814547-25-000030.md) | [122](/filings/0000814547-25-000008.md) | [71.0 d](/filings/0000814547-25-000014.md) | [213 d](/filings/0000814547-25-000022.md) | [226 d](/filings/0000814547-25-000030.md) | [194](/filings/0000814547-26-000011.md) | [74.9 d](/filings/0000814547-26-000021.md) | [286 d](/filings/0000814547-26-000030.md) | [224 d](/filings/0000814547-25-000030.md) | [174](/filings/0000814547-26-000011.md) | [223 d](/filings/0000814547-26-000021.md) | [380 d](/filings/0000814547-26-000030.md) |
| Capital expenditure | $m | [1.1 d](/filings/0000814547-25-000030.md) | [1.4](/filings/0000814547-25-000008.md) | [4.0 d](/filings/0000814547-25-000014.md) | [1.7 d](/filings/0000814547-25-000022.md) | [1.8 d](/filings/0000814547-25-000030.md) | [0.8](/filings/0000814547-26-000011.md) | [2.1 d](/filings/0000814547-26-000021.md) | [1.8 d](/filings/0000814547-26-000030.md) | [4.2 d](/filings/0000814547-25-000030.md) | [0.2](/filings/0000814547-26-000011.md) | [0.3 d](/filings/0000814547-26-000021.md) | [0.9 d](/filings/0000814547-26-000030.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | [120 d](/filings/0000814547-25-000030.md) | [71.7](/filings/0000814547-25-000008.md) | [172 d](/filings/0000814547-25-000014.md) | [255 d](/filings/0000814547-25-000022.md) | [324 d](/filings/0000814547-25-000030.md) | [163](/filings/0000814547-26-000011.md) | [217 d](/filings/0000814547-26-000021.md) | [487 d](/filings/0000814547-26-000030.md) | [548 d](/filings/0000814547-25-000030.md) | [171](/filings/0000814547-26-000011.md) | [605 d](/filings/0000814547-26-000021.md) | [2,269 d](/filings/0000814547-26-000030.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2022-12-31) | Q2 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [25.4](/filings/0000814547-24-000005.md) | [25.4](/filings/0000814547-24-000016.md) | [25.3](/filings/0000814547-24-000024.md) | [25.2](/filings/0000814547-25-000008.md) | [25.2](/filings/0000814547-25-000014.md) | [25.0](/filings/0000814547-25-000022.md) | [24.8](/filings/0000814547-26-000011.md) | [24.7](/filings/0000814547-26-000021.md) | [24.6](/filings/0000814547-26-000030.md) | [24.0](/filings/0000814547-26-000011.md) | [23.7](/filings/0000814547-26-000021.md) | [22.7](/filings/0000814547-26-000030.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 21,597,635 at 2026-07-17, from the cover of the [10-Q filed 2026-07-29](/filings/0000814547-26-000030.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:25 ET. No prices; not investment advice.